Syddansk Universitet Identification of high-risk patients by human epididymis protein 4 levels during follow- up of ovarian cancer

The majority of ovarian cancer patients with advanced disease at diagnosis will relapse following primary treatment, with a dismal prognosis. Monitoring the levels of serum markers in patients under follow-up may be essential for the early detection of relapse, and for distinguishing high-risk patients from those with less aggressive disease. The aim of the present study was to investigate the possible predictive value of human epididymis protein 4 (HE4) and carbohydrate antigen 125 (CA125) in relation to recurrence of epithelial ovarian cancer by measuring the two markers during follow-up subsequent to surgery and adjuvant first‐line carboplatin/paclitaxel chemotherapy. Serum HE4 and CA125 were analyzed in 88 epithelial ovarian cancer patients at the end of treatment and consecutively during follow-up. The patients were divided into a high-risk and a low-risk group based on having an increase in HE4 and CA125 levels above or below 50% during follow-up, relative to the baseline (end-of-treatment) level. Disease recurrence was detected in 55 patients during follow-up. Patients with an increase in HE4 of >50% at 3and 6-month follow-up compared to the end-of-treatment sample had significantly poorer progression-free survival (PFS) [hazard ratio (HR), 2.82 (95% CI, 0.91-8.79; P=0.0052) and HR, 7.71 (95% CI, 3.03-19.58; P<0.0001), respectively]. The corresponding 3and 6-month biomarker assessments for increased CA125 levels (>50%) showed HRs of 1.86 (95% CI, 0.90-3.80; P=0.0512) and 2.55 (95% CI, 1.39-4.68; P=0.0011), respectively. Multivariate analysis confirmed HE4 as a predictor of short PFS, with an HR of 8.23 (95% CI, 3.28-20.9; P<0.0001) at 6-month follow-up. The increase of CA125 was not a significant prognostic factor in multivariate analysis for PFS. In conclusion, HE4 appears to be a sensitive marker of recurrence and instrumental in risk assessment during the first 6 months of follow‐up.

[1]  L. Frati,et al.  Serum HE4 levels combined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer. , 2013, Oncology reports.

[2]  R. Angioli,et al.  Does HE4 have a role as biomarker in the recurrence of ovarian cancer? , 2012, Tumor Biology.

[3]  Karina Dahl Steffensen,et al.  The Prognostic and Predictive Value of Combined HE4 and CA-125 in Ovarian Cancer Patients , 2012, International Journal of Gynecologic Cancer.

[4]  Luigi Frati,et al.  Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer , 2012, Tumor Biology.

[5]  M. Schummer,et al.  Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. , 2012, Gynecologic oncology.

[6]  B. Karlan,et al.  CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. , 2011, Gynecologic oncology.

[7]  I. Hellstrom,et al.  fTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma. , 2011, Expert opinion on medical diagnostics.

[8]  I. Brandslund,et al.  Prognostic Impact of Prechemotherapy Serum Levels of HER2, CA125, and HE4 in Ovarian Cancer Patients , 2011, International Journal of Gynecologic Cancer.

[9]  Corneel Coens,et al.  Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial , 2010, The Lancet.

[10]  L. Frati,et al.  HE4: a new potential early biomarker for the recurrence of ovarian cancer , 2010, Tumor Biology.

[11]  K. Steffensen,et al.  The Relationship of Platinum Resistance and ERCC1 Protein Expression in Epithelial Ovarian Cancer , 2009, International Journal of Gynecologic Cancer.

[12]  Qin He,et al.  Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. , 2008, Gynecologic oncology.

[13]  Thorsten Verch,et al.  The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. , 2008, Gynecologic oncology.

[14]  D. Alberts,et al.  An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  H. Frierson,et al.  Comprehensive analysis of HE4 expression in normal and malignant human tissues , 2006, Modern Pathology.

[16]  Y. Bourbonnais,et al.  Proteins with whey-acidic-protein motifs and cancer. , 2006, The Lancet. Oncology.

[17]  Christopher P Crum,et al.  Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. , 2005, Cancer research.

[18]  Michèl Schummer,et al.  The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. , 2003, Cancer research.

[19]  G. Rustin,et al.  Use of CA-125 to assess response to new agents in ovarian cancer trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Lilja,et al.  A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. , 2002, The Biochemical journal.

[21]  P. Dombernowsky,et al.  Serum tumor marker CA 125 for monitoring ovarian cancer during follow-up , 2002, Scandinavian journal of clinical and laboratory investigation.

[22]  M. Parmar,et al.  Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. , 2000, Journal of the National Cancer Institute.

[23]  G. Rustin,et al.  Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  R. Bast,et al.  Preoperative Evaluation of Serum CA 125 Levels in Patients With Primary Epithelial Ovarian Cancer , 1986, Obstetrics and gynecology.

[25]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[26]  G. Lippi,et al.  The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass , 2009, Journal of clinical laboratory analysis.

[27]  Richard G. Moore,et al.  A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. , 2009, Gynecologic oncology.

[28]  I. Hellstrom,et al.  SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. , 2008, Advances in experimental medicine and biology.

[29]  E. Eisenhauer,et al.  Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). , 2005, Journal of the National Cancer Institute.

[30]  Ethical principles for medical research involving human subjects. , 2001, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.